Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$377.85 - $519.88
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.56M
Market Cap
$118.67B
Enterprise Value$100.53B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Apr 30, 2025EPS Estimate
4.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding256,789,860
10 Day Avg. Volume1,334,372
30 Day Avg. Volume1,564,593
Standard Deviation0.08
R-Squared0.08
Alpha0.00987
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.77
Price to Cash Flow (P/CF)50.80
P/FCF Ratio50.40
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.59
Enterprise Value/Ebitda206.73
Forecast
1Y Price Target
$499.91Price Target Upside5.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
---
Bulls Say, Bears Say
Bulls Say
EarningsVertex reported 4Q24 results with revenue of $2.9B, exceeding consensus of $2.78B, and non-GAAP EPS of $3.98, vs. $3.57 consensus.
Financial StabilityVertex ended the quarter with $11.2B in cash and marketable securities and no debt.
Pipeline And InnovationThe FDA approved Alyftrek, a next-generation therapy, which is expected to be accretive to Vertex over time.
Bears Say
Product CompetitionJournavx, despite its FDA approval, is not expected to be highly competitive due to its slow onset of action.
Product UptakeCaution is advised about the rate of uptake and the ultimate opportunity in acute pain for Journavx.
Valuation ConcernsVertex shares are currently at a premium valuation with a P/E multiple significantly higher than the mega-cap BioPharma peer average.
---
Ownership Overview
0.27% Insiders
36.08% Mutual Funds
30.26% Other Institutional Investors
9.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $377.85 and its highest was $519.88 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $118.67B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Apr 30, 2025 which is in 68 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported $3.98 earnings per share for the quarter, missing the consensus estimate of $4.016 by -$0.036.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.26.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 256,789,860 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $3.98 in its last earnings report, missing expectations of $4.016. Following the earnings report the stock price went down -3.138%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$499.91 (5.97% Upside)
$499.91 (5.97% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 96%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 17.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.73%
12-Months-Change
Fundamentals
Return on Equity
-3.26%
Trailing 12-Months
Asset Growth
0.02%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VRTX Company Deck
---
VRTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful product launches, signaling a positive momentum for Vertex's commercial and R&D efforts. However, the call also acknowledged challenges such as IP violations in Russia and increased operating expenses affecting profitability.Read More>---
VRTX Revenue Breakdown
60.66% U.S.
39.34% Europe
---
VRTX Stock 12 Month Forecast
Average Price Target
$499.91
▲(5.97% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
25/32 ratings generated profit
1 Year Average Return
+22.73%
reiterated a buy rating 12 days ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 78.13% of your transactions generating a profit, with an average return of +22.73% per trade.
---